Cue Biopharma, Inc.

CUE · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders8.8%

Institutions22.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$27.47M	$9.29M	$1.25M	$14.94M	$3.15M	$3.46M	$1.14M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$26.55M	-$41.50M	-$53.22M	-$43.71M	-$45.04M	-$36.77M	-$38.70M
Operating income as a percentage of revenue.	-96.7%	-446.9%	-4274.3%	-292.6%	-1428.0%	-1063.2%	-3386.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$26.60M	-$40.67M	-$53.01M	-$44.16M	-$44.78M	-$36.70M	-$38.98M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$-1.00	$-1.41	$-1.56	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$-1.00	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$27.14M	$22.46M	$51.61M	$64.37M	$74.87M	$44.29M	–
Everything the company owns that has value — cash, property, inventory, investments, and more.	$42.21M	$32.19M	$91.28M	$83.40M	$99.53M	$71.61M	$45.36M
All of the company's interest-bearing borrowings, short and long term combined.	$0	$4.33M	$10.00M	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$15.78M	$14.69M	$25.60M	$17.91M	$20.62M	$17.02M	$11.39M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$26.43M	$17.50M	$65.68M	$65.49M	$78.91M	$54.58M	$33.97M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$21.69M	-$36.33M	-$41.81M	-$38.84M	-$32.49M	-$30.80M	-$26.41M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$177000	$66000	$170746	$913039	$595259	$46353	$1.85M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$21.86M	-$36.40M	-$41.98M	-$39.75M	-$33.09M	-$30.84M	-$28.27M

	You	Peer avg
Revenue Growth	+166.7%	–
ROE	-1603.5%	-47.6%

Cue Biopharma, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison